{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:11:51Z","timestamp":1792289511505,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.biopha.2018.02.059","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:25:28Z","timestamp":1519345528000},"page":"495-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Oral administration effects of \u03b2-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis"],"prefix":"10.1016","volume":"100","author":[{"given":"Mohammad Javad","family":"Fattahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Jafarnezhad-Ansariha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Shahabeddin","family":"Mortazavi-Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd H.A.","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Mirshafiey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.02.059_bib0005","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2018.02.059_bib0010","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","article-title":"The classification and diagnostic criteria of ankylosing spondylitis","volume":"48","author":"Raychaudhuri","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.biopha.2018.02.059_bib0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2010.79","article-title":"Pathogenesis of ankylosing spondylitis","volume":"6","author":"Tam","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0020","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci","volume":"45","author":"Cortes","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2018.02.059_bib0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/TACG.S37325","article-title":"The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis","volume":"7","author":"Tsui","year":"2014","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.biopha.2018.02.059_bib0030","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/rheumatology\/kev218","article-title":"Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis","volume":"54","author":"Kenna","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.biopha.2018.02.059_bib0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","article-title":"The interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.it.2011.08.003","article-title":"Deciphering the role of Th17 cells in human disease","volume":"32","author":"Wilke","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","article-title":"Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti \u2013 TNF-\u03b1 therapy","volume":"33","author":"Li","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0050","doi-asserted-by":"crossref","first-page":"e31000","DOI":"10.1371\/journal.pone.0031000","article-title":"Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.02.059_bib0055","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2018.02.059_bib0060","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar3257","article-title":"Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+ CCR6+ Th\/Treg cell subset imbalance in ankylosing spondylitis","volume":"13","author":"Wu","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2018.02.059_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2161-1149.1000119","article-title":"Overview of drug therapy for spondyloarthritis","volume":"3","author":"Keith","year":"2013","journal-title":"Rheumatol. Curr. Res."},{"key":"10.1016\/j.biopha.2018.02.059_bib0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/08923973.2015.1113296","article-title":"Preclinical assessment of beta-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug","volume":"37","author":"Fattahi","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0075","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.pharep.2017.04.015","article-title":"Introduction of \u03b2-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1\/COX-2 activity and gene expression","volume":"69","author":"Mirshafiey","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2018.02.059_bib0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1081\/IPH-200067751","article-title":"Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis","volume":"27","author":"Mirshafiey","year":"2005","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0085","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.etap.2007.02.002","article-title":"Production of M2000 (beta-d-mannuronic acid) and its therapeutic effect on experimental nephritis","volume":"24","author":"Mirshafiey","year":"2007","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/08923970701282387","article-title":"Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis","volume":"29","author":"Mirshafiey","year":"2007","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1570163814666170321113059","article-title":"The potent inhibitory effect of beta-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on anti-cyclic citrullinated peptide antibodies, rheumatoid factor and anti-dsDNA antibodies in patients with rheumatoid arthritis","volume":"14","author":"Ahmadi","year":"2017","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0100","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2147\/DDDT.S129419","article-title":"Effects of beta-d-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, RORgammat, IL4 and GATA3 gene expressions in rheumatoid arthritis patients","volume":"11","author":"Barati","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2018.02.059_bib0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.pharep.2017.01.021","article-title":"Pharmacological effects of \u03b2-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-\u03baB gene expression, as target molecules in inflammatory reactions","volume":"69","author":"Mortazavi-Jahromi","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2018.02.059_bib0110","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2796.2008.01950.x","article-title":"The interleukin-23\/interleukin-17 axis in intestinal inflammation","volume":"263","author":"Maloy","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.biopha.2018.02.059_bib0115","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2018.02.059_bib0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.biopha.2018.02.059_bib0125","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","article-title":"Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis","volume":"74","author":"Wendling","year":"2007","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.biopha.2018.02.059_bib0130","first-page":"PI53","article-title":"M2000: a revolution in pharmacology","volume":"11","author":"Mirshafiey","year":"2005","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.biopha.2018.02.059_bib0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/sji.12519","article-title":"M2000 (\u03b2-D-mannuronic acid) as a novel antagonist for blocking the TLR2 and TLR4 downstream signalling pathway","volume":"85","author":"Aletaha","year":"2017","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0140","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/eji.200838969","article-title":"Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN\u2010\u03b3 production by memory CD4+ T cells","volume":"39","author":"Napolitani","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0145","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2018.02.059_bib0150","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1016\/j.febslet.2011.07.043","article-title":"Regulatory T\u2010cells in systemic lupus erythematosus and rheumatoid arthritis","volume":"585","author":"Chavele","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2018.02.059_bib0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-3083.2005.01656.x","article-title":"The presence of cytokine\u2010suppressive CD4+ CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis","volume":"62","author":"Liu","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0160","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellimm.2008.05.007","article-title":"CD4+ CD25 high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis","volume":"253","author":"Han","year":"2008","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.biopha.2018.02.059_bib0165","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1084\/jem.194.5.629","article-title":"Cell contact\u2013dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface\u2013bound transforming growth factor \u03b2","volume":"194","author":"Nakamura","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2018.02.059_bib0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jbspin.2015.03.003","article-title":"Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment","volume":"82","author":"Liao","year":"2015","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.biopha.2018.02.059_bib0175","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22010134","article-title":"Therapeutic potential of targeting the Th17\/Treg axis in autoimmune disorders","volume":"22","author":"Fasching","year":"2017","journal-title":"Molecules"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217366556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217366556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:11:09Z","timestamp":1761243069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217366556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":35,"alternative-id":["S0753332217366556"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.02.059","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral administration effects of \u03b2-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.02.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}